Organogenesis Holdings INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Organogenesis Holdings Inc. reported a significant increase in net product revenue for fiscal year 2025, driven by Advanced Wound Care products, while navigating evolving Medicare reimbursement policies and advancing its ReNu BLA submission.
NASDAQ
Organogenesis Holdings Inc. files an amendment to its 2024 annual report on Form 10-K to include Part III information regarding directors, executive officers, corporate governance, and executive compensation.
NASDAQ
10-K: Organogenesis Holdings Inc. Reports 2024 Annual Results, Outlines Strategic Growth Initiatives
Organogenesis Holdings Inc. files its 10-K report for the fiscal year ended December 31, 2024, detailing its financial performance and strategic plans for growth in the regenerative medicine and tissue innovation markets.
NASDAQ
Organogenesis Holdings Inc. reported its full year 2023 financial results, highlighting revenue of $433.1 million and a net income of $4.9 million.